Contera Pharma will receive an upfront payment and full research funding for each target under investigation
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
AbCellera will receive an upfront payment and is eligible to receive additional milestone payments
The global VR market to grow at a compound annual growth rate of 13% from $7 billion in 2018 to $28 billion in 2030.
Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders
Entos will receive an initial payment of US $50 million, which includes an equity investment by Lilly
Advancing toward Phase 2a evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track designation
New test expands access to early Alzheimer’s assessment, streamlining diagnostic pathways and improving referral efficiency
New study presents a human-relevant stress model for assessing potential therapeutics
Agency initiates safety label change and notifies physicians of possible link
Subscribe To Our Newsletter & Stay Updated
